Occult hepatitis B infection in chronic hemodialysis patients: Current concepts and strategy

Hepatitis Monthly

Volumn 10, Issue 3, 2010, Pages 199-204

  Hollinger, F Blaine ^a   Habibollahi, Peiman ^b   Daneshmand, Ali ^b   Alavian, Seyed Moayed ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

HBV; Hemodialysis; Occult hepatitis B

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

CHRONICITY; COMORBIDITY; DISEASE COURSE; DISEASE TRANSMISSION; EPIDEMIC; GENOTYPE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPATITIS B; HEPATITIS C; HUMAN; INCIDENCE; KIDNEY FAILURE; LONG TERM CARE; PREVALENCE; PROMOTER REGION; REVIEW; RISK FACTOR; SENSITIVITY ANALYSIS; VIRUS REPLICATION;

EID: 77954875607     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Brechot C, Degos F, Lugassy C, et al. Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med. 1985;312(5):270-6.
2. Chazouilleres O, Mamish D, Kim M, et al. "Occult" hepatitis B virus as source of infection in liver transplant recipients. Lancet. 1994;343(8890):142-6.
3. Dickson RC, Everhart JE, Lake JR, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology. 1997;113(5):1668-74.
4. Prieto M, Gomez MD, Berenguer M, et al. De novo hepatitis B after liver transplantation from hepatitis B core antibodypositive donors in an area with high prevalence of anti- HBc positivity in the donor population. Liver Transpl. 2001;7(1):51-8.
5. Samuel D, Forns X, Berenguer M, et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol. 2006;45(1):127-43.
6. Chemin I, Zoulim F, Merle P, et al. High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology. J Hepatol. 2001;34(3):447-54.
7. Fang Y, Shang QL, Liu JY, et al. Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China. J Infect. 2009;58(5):383-8.
8. Matsuoka S, Nirei K, Tamura A, et al. Influence of occult hepatitis B virus coinfection on the incidence of fibrosis and hepatocellular carcinoma in chronic hepatitis C. Intervirology. 2008;51(5):352-61.
9. Tamori A, Hayashi T, Shinzaki M, et al. Frequent detection of hepatitis B virus DNA in hepatocellular carcinoma of patients with sustained virologic response for hepatitis C virus. J Med Virol. 2009;81(6):1009-14.
10. Squadrito G, Pollicino T, Cacciola I, et al. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer. 2006;106(6):1326-30.
11. Hollinger FB, Sood G. Occult hepatitis B virus infection: a covert operation. J Viral Hepat. 2010;17(1):1-15.
12. Prodjosudjadi W. Incidence, prevalence, treatment and cost of end-stage renal disease in Indonesia. Ethn Dis. 2006;16(2 Suppl 2):S2-14-6.
13. Haghighi AN, Broumand B, D'Amico M, Locatelli F, Ritz E. The epidemiology of end-stage renal disease in Iran in an international perspective. Nephrol Dial Transplant. 2002;17(1):28-32.
14. Mahdavi-Mazdeh M, Zamyadi M, Nafar M. Assessment of management and treatment responses in haemodialysis patients from Tehran province, Iran. Nephrol Dial Transplant. 2008;23(1):288-93.
15. Mazzoni A, Innocenti M, Consaga M. Retrospective study on the prevalence of B and non-A, non-B hepatitis in a dialysis unit: 17-year follow-up. Nephron. 1992;61(3):316-7.
16. Petrosillo N, Puro V, Ippolito G. Prevalence of human immunodeficiency virus, hepatitis B virus and hepatitis C virus among dialysis patients. The Italian Multicentric Study on Nosocomial and Occupational Risk of Blood-Borne Infections in Dialysis. Nephron. 1993;64(4):636-9.
17. Reddy GA, Dakshinamurthy KV, Neelaprasad P, Gangadhar T, Lakshmi V. Prevalence of HBV and HCV dual infection in patients on haemodialysis. Indian J Med Microbiol. 2005;23(1):41-3.
18. Alavian SM, Bagheri-Lankarani K, Mahdavi-Mazdeh M, Nourozi S. Hepatitis B and C in dialysis units in Iran: changing the epidemiology. Hemodial Int. 2008;12(3):378- 82.
19. Albertoni F, Battilomo A, Di Nardo V, et al. Evaluation of a region-wide hepatitis B vaccination program in dialysis patients: experience in an Italian region. The Latium Hepatitis Prevention Group. Nephron. 1991;58(2):180-3.
20. Fabrizi F, Mangano S, Alongi G, et al. Influence of hepatitis B virus virema upon serum aminotransferase activity in dialysis population. Int J Artif Organs. 2003;26(12):1048- 55.
21. Hutin YJ, Goldstein ST, Varma JK, et al. An outbreak of hospital-acquired hepatitis B virus infection among patients receiving chronic hemodialysis. Infect Control Hosp Epidemiol. 1999;20(11):731-5.
22. Schmilovitz-Weiss H, Melzer E, Tur-Kaspa R, Ben-Ari Z. Excellent outcome of Lamivudine treatment in patients with chronic renal failure and hepatitis B virus infection. J Clin Gastroenterol. 2003;37(1):64-7.
23. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005;18(1):52-61.
24. Teles SA, Martins RM, Vanderborght B, Stuyver L, Gaspar AM, Yoshida CF. Hepatitis B virus: genotypes and subtypes in Brazilian hemodialysis patients. Artif Organs. 1999;23(12):1074-8.
25. Tokars JI, Alter MJ, Favero MS, Moyer LA, Miller E, Bland LA. National surveillance of dialysis associated diseases in the United States, 1992. ASAIO J. 1994;40(4):1020-31.
26. Burdick RA, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2003;63(6):2222-9.
27. Cendoroglo Neto M, Draibe SA, Silva AE, et al. Incidence of and risk factors for hepatitis B virus and hepatitis C virus infection among haemodialysis and CAPD patients: evidence for environmental transmission. Nephrol Dial Transplant. 1995;10(2):240-6.
28. Miller ER, Alter MJ, Tokars JI. Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis. 1999;33(2):356-60.
29. DaRoza G, Loewen A, Djurdjev O, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis. 2003;42(6):1184-92.
30. Harnett JD, Parfrey PS, Kennedy M, Zeldis JB, Steinman TI, Guttmann RD. The long-term outcome of hepatitis B infection in hemodialysis patients. Am J Kidney Dis. 1988;11(3):210-3.
31. Chow KM, Szeto CC, Wu AK, Leung CB, Kwan BC, Li PK. Continuous ambulatory peritoneal dialysis in patients with hepatitis B liver disease. Perit Dial Int. 2006;26(2):213-7.
32. Tanaka S, Yoshiba M, Iino S, et al. A common-source outbreak of fulminant hepatitis B in hemodialysis patients induced by precore mutant. Kidney Int. 1995;48(6):1972-8.
33. Coughlin GP, Van Deth AG, Disney AP, Hay J, Wangel AG. Liver disease and the e antigen in HBsAg carriers with chronic renal failure. Gut. 1980;21(2):118-22.
34. Degott C, Degos F, Jungers P, et al. Relationship between liver histopathological changes and HBsAg in 111 patients treated by long-term hemodialysis. Liver. 1983;3(6):377-84.
35. Lai KN, Tam JS, Lai FM, Lin HJ. Isolated presence of antibody to hepatitis B core antigen in dialysis patients: occurrence of subclinical hepatitis?. Am J Kidney Dis. 1989;13(5):370-6.
36. Hoofnagle JH, Seeff LB, Bales ZB, Zimmerman HJ. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med. 1978;298(25):1379- 83.
37. Sanchez-Quijano A, Jauregui JI, Leal M, et al. Hepatitis B virus occult infection in subjects with persistent isolated anti-HBc reactivity. J Hepatol. 1993;17(3):288-93.
38. Joller-Jemelka HI, Wicki AN, Grob PJ. Detection of HBs antigen in "anti-HBc alone" positive sera. J Hepatol. 1994;21(2):269-72.
39. Cabrerizo M, Bartolome J, De Sequera P, Caramelo C, Carreno V. Hepatitis B virus DNA in serum and blood cells of hepatitis B surface antigen-negative hemodialysis patients and staff. J Am Soc Nephrol. 1997;8(9):1443-7.
40. Minuk GY, Sun DF, Greenberg R, et al. Occult hepatitis B virus infection in a North American adult hemodialysis patient population. Hepatology. 2004;40(5):1072-7.
41. Jain P, Nijhawan S. Occult hepatitis C virus infection is more common than hepatitis B infection in maintenance hemodialysis patients. World J Gastroenterol. 2008;14(14):2288-9.
42. Fabrizi F, Messa PG, Lunghi G, et al. Occult hepatitis B virus infection in dialysis patients: a multicentre survey. Aliment Pharmacol Ther. 2005;21(11):1341-7.
43. Di Stefano M, Volpe A, Stallone G, et al. Occult HBV infection in hemodialysis setting is marked by presence of isolated antibodies to HBcAg and HCV. J Nephrol. 2009;22(3):381-6.
44. Yakaryilmaz F, Gurbuz OA, Guliter S, et al. Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. Ren Fail. 2006;28(8):729-35.
45. Altindis M, Uslan I, Cetinkaya Z, et al. [Investigation of hemodialysis patients in terms of the presence of occult hepatitis B]. Mikrobiyol Bul. 2007;41(2):227-33.
46. Cabrerizo M, Bartolome J, Caramelo C, Barril G, Carreno V. Molecular analysis of hepatitis B virus DNA in serum and peripheral blood mononuclear cells from hepatitis B surface antigen-negative cases. Hepatology. 2000;32(1):116-23.
47. Goral V, Ozkul H, Tekes S, Sit D, Kadiroglu AK. Prevalence of occult HBV infection in haemodialysis patients with chronic HCV. World J Gastroenterol. 2006;12(21):3420-4.
48. Besisik F, Karaca C, Akyuz F, et al. Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection. J Hepatol. 2003;38(4):506-10.
49. Kanbay M, Gur G, Akcay A, et al. Is hepatitis C virus positivity a contributing factor to occult hepatitis B virus infection in hemodialysis patients?. Dig Dis Sci. 2006;51(11):1962-6.
50. Siagris D, Christofidou M, Triga K, et al. Occult hepatitis B virus infection in hemodialysis patients with chronic HCV infection. J Nephrol. 2006;19(3):327-33.
51. Shetty K, Hussain M, Nei L, Reddy KR, Lok AS. Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl. 2008;14(4):534-40.
52. Mahmoud IM, Elhabashi AF, Elsawy E, El-Husseini AA, Sheha GE, Sobh MA. The impact of hepatitis C virus viremia on renal graft and patient survival: a 9-year prospective study. Am J Kidney Dis. 2004;43(1):131-9.
53. Perez RM, Ferreira AS, Medina-Pestana JO, Lanzoni VP, Silva AE, Ferraz ML. Is alanine aminotransferase a good marker of histologic hepatic damage in renal transplant patients with hepatitis C virus infection?. Clin Transplant. 2005;19(5):622-5.